早期可手术乳腺癌的诊治现状与展望
Diagnosis and treatment in early operable breast cancer: current status and prospect
陈小松, 沈坤炜, 李宏为 . 早期可手术乳腺癌的诊治现状与展望[J]. 外科理论与实践, 2022 , 27(05) : 385 -386 . DOI: 10.16139/j.1007-9610.2022.05.001
| [1] | Loibl S, Poortmans P, Morrow M, et al. Breast cancer[J]. Lancet, 2021, 397(10286):1750-1769. |
| [2] | Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs. no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial[J]. JAMA, 2017, 318(10): 918-926. |
| [3] | Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases(IBCSG 23-01):10-year follow-up of a randomised, controlled phase 3 trial[J]. Lancet Oncol, 2018, 19(10):1385-1393. |
| [4] | Simons JM, van der Pol CC, et al. Diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer[J]. JAMA Surg, 2022, e223907. |
| [5] | Masuda N, Lee S, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med, 2017, 376(22):2147-2159. |
| [6] | von Minckwitz G, Huang CS, Mano MS, et al. Trastuzu-mab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med, 2019, 380(7):617-628. |
| [7] | Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer[J]. N Engl J Med, 2022, 386(6):556-567. |
| [8] | Tutt AN, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer[J]. N Engl J Med, 2021, 384(25):2394-2405. |
| [9] | Harbeck N, Rastogi P, Martin M, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study[J]. Ann Oncol, 2021, 32(12):1571-1581. |
| [10] | Mateo J, Steuten L, Aftimos P, et al. Delivering precision oncology to patients with cancer[J]. Nat Med, 2022, 28(4):658-665. |
/
| 〈 |
|
〉 |
